Cover Image
市場調查報告書

EpiCast Report:偏頭痛的流行病學的預測

EpiCast Report: Migraine - Epidemiology Forecast to 2026

出版商 GlobalData 商品編碼 296020
出版日期 內容資訊 英文 30 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:偏頭痛的流行病學的預測 EpiCast Report: Migraine - Epidemiology Forecast to 2026
出版日期: 2017年08月10日 內容資訊: 英文 30 Pages
簡介

全球主要7個國家偏頭痛的患病人數,2013年為7638萬人,2023年為7583萬人,預計持續維持與現在同樣的水準。美國的患病人數最多,2013年為2961萬人,2023年推算為3113萬人。

本報告提供全球主要7個國家(美國、法國、德國、義大利、西班牙、英國、日本)的糖尿病神經病變的發病情形和今後預測相關分析、疾病的特徵(風險要素和主要的共生病症等等)全球各國的趨勢、目前患病者的發病情形、今後10年的患病數量的預測值等調查評估,並將其結果依為您概述為以下內容。

第1章 目錄

第2章 簡介

  • 概要

第3章 流行病學

  • 疾病的背景
  • 風險要素和共生病症
    • 女性和有無家族病史,有風險要素相關性
    • 偏頭痛患者也患有其他幾個共生病症
  • 全世界的趨勢
    • 美國
    • 歐洲主要5個國家
    • 日本
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法
  • 偏頭痛的流行病學預測(今後11年份)
    • 偏頭痛的患病人數:總數
    • 偏頭痛的患病人數:各年齡
    • 偏頭痛的患病人數:男女
    • 偏頭痛的患病人數(已調整年齡)
    • 偏頭痛的患病人數:如果沒有徵兆的情況
  • 議論
    • 流行病學性的趨勢相關結論
    • 分析的限制
    • 分析的優勢

第4章 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHCER158-17

Migraine is typically characterized by recurring headaches and throbbing pain on one side of the head accompanied by nausea, vomiting, or increased sensitivity to light or smell (Bigal and Lipton, 2006). While most migraineurs experience episodic migraines (EM), a small percentage suffers from chronic migraine (CM). Migraines are also classified into migraine with aura (MWA), in which the migraine is accompanied by other sensory symptoms, and migraine without aura (MOA).

In 2016, there were 73,914,635 total prevalent cases of migraine in adults ages 18 years and older in the 7MM. The US had the most cases, with 30,233,942, making up 40.90% of cases in the 7MM. Italy had the second most cases, with 12,231,868 cases, or 16.55% of cases in the 7MM. Spain had the fewest cases, with 2,199,892 cases (2.98% of cases in the 7MM). Italy also had the highest prevalence of migraine, with 23.63% of adult's ages 18 years and older experiencing migraine in 2016. Spain had the lowest prevalence, at 5.54%.

In the 7MM, the number of total prevalent cases of migraine is expected to grow to 74,543,569 by 2026, at an Annual Growth Rate (AGR) of 0.09%. The US, France, Spain, and the UK are expected to see small increases in the number of total prevalent migraine cases, while Germany, Italy, and Japan are expected to see small decreases. The largest changes are expected in the US (AGR 0.60%) and Japan (AGR negative 0.87%). Since age- and sex-specific prevalence was held constant throughout the forecast period, all changes in the total prevalent cases of migraine are the result of demographic changes.

Our epidemiologists estimate that 1.61% of total migraine cases in the 7MM in 2016 were CM, corresponding to 1,189,614 cases. Due to the lack of country-specific sources, this percentage was applied to all markets.

The report "EpiCast Report: Migraine - Epidemiology Forecast to 2026" provides an overview of the risk factors, comorbidities, and the global and historical trends for migraine in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases (diagnosed and undiagnosed) of migraine segmented by sex and age (for ages 18 years and older) in these markets. This forecast is further segmented by migraine frequency into EM and CM.

Scope

  • The Migraine EpiCast Report provides an overview of the risk factors and global trends of migraine in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases of migraine segmented by sex and age (for ages 18 years and older) in these markets. This forecast is further segmented by migraine frequency into episodic migraine (EM) and chronic migraine (CM).
  • The migraine epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Migraine EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global migraine market.
  • Quantify patient populations in the global migraine market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for migraine therapeutics in each of the markets covered.
  • Identify the percentage of migraine prevalent cases by frequency.

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 3
  • 1.2 List of Figures 3

2 Executive Summary 4

  • 2.1 Related Reports 5
  • 2.2 Upcoming Reports 5

3 Epidemiology 6

  • 3.1 Disease Background 6
  • 3.2 Risk Factors and Comorbidities 6
  • 3.3 Global and Historical Trends 9
    • 3.3.1 US 10
    • 3.3.2 5EU 11
    • 3.3.3 Japan 11
  • 3.4 Forecast Methodology 11
    • 3.4.1 Sources 12
    • 3.4.2 Forecast Assumptions and Methods 14
  • 3.5 Epidemiological Forecast for Migraine (2016-2026) 17
    • 3.5.1 Total Prevalent Cases of Migraine 17
    • 3.5.2 Age-Specific Total Prevalent Cases of Migraine 18
    • 3.5.3 Sex-Specific Total Prevalent Cases of Migraine 19
    • 3.5.4 Migraine Cases by Frequency of Occurrences 20
  • 3.6 Discussion 21
    • 3.6.1 Epidemiological Forecast Insight 21
    • 3.6.2 Limitations of Analysis 22
    • 3.6.3 Strengths of Analysis 23

4 Appendix 24

  • 4.1 Bibliography 24
  • 4.2 About the Authors 28
    • 4.2.1 Epidemiologist 28
    • 4.2.2 Reviewers 28
    • 4.2.3 Global Director of Therapy Analysis and Epidemiology 29
    • 4.2.4 Global Head and EVP of Healthcare Operations and Strategy 29
  • 4.3 About GlobalData 30
  • 4.4 Contact Us 30
  • 4.5 Disclaimer 30

List of Tables

1.1 List of Tables

  • Table 1: Risk Factors and Comorbidities for Migraine 8
  • Table 2: ICHD-3 Diagnostic Criteria for Migraine 12
  • Table 3: Total Prevalent Cases of Migraine, Ages ≥18 Years, Both Sexes, N, Select Years 2016-2026 18

List of Figures

1.2 List of Figures

  • Figure 1: 7MM, Total Prevalent Cases of Migraine, Both Sexes, Ages ≥18 Years, 2016 and 2026 5
  • Figure 2: 7MM, Age-Standardized Total Prevalence of Migraine, Both Sexes, Ages ≥18 Years, 2016 10
  • Figure 3: Sources Used and Not Used in Epidemiological Analysis of Migraine Prevalence 13
  • Figure 4: Sources Used and Not Used in Epidemiological Analysis of Migraine Frequency 14
  • Figure 5: 7MM, Age-Specific Total Prevalent Cases of Migraine, Both Sexes, Ages ≥18 Years, 2016 19
  • Figure 6: 7MM, Sex-Specific Total Prevalent Cases of Migraine, Ages ≥18 Years, 2016 20
  • Figure 7: 7MM, Total Prevalent Migraine Cases by Frequency of Occurrences, Both Sexes, Ages ≥18 Years, 2016 21
Back to Top